To reveal the functional significance of hypoxia and angiogenesis in astrocytoma progression, we created genetically engineered transformed astrocytes from murine primary astrocytes and deleted the hypoxia-responsive transcription factor HIF-1␣ or its target gene, the angiogenic factor VEGF. Growth of HIF-1␣-and VEGF-deficient transformed astrocytes in the vessel-poor subcutaneous environment results in severe necrosis, reduced growth, and vessel density, whereas when the same cells are placed in the vascular-rich brain parenchyma, the growth of HIF-1␣ knockout, but not VEGF knockout tumors, is reversed: tumors deficient in HIF-1␣ grow faster, and penetrate the brain more rapidly and extensively. These results demonstrate that HIF-1␣ has differential roles in tumor progression, which are greatly dependent on the extant microenvironment of the tumor.
Introduction
1999a) and increased tumor cell proliferation (Brat et al., 2002; Holland, 2000) . The resultant hypoxia is then thought to induce Every tissue, including solid tumors, is dependent on adequate new blood vessels that supply the tumor with the necessary oxygen delivery. Angiogenesis, the formation of new blood vesmetabolites (Brat et al., 2003) . In fact, glioblastomas are in part sels, is a discrete step in tumor progression that is required for defined by the appearance of proliferating endothelial cells and the expansion of tumor mass (Folkman, 2000) . The stage in high blood vessel densities; these distinguish grade IV tumors which angiogenesis is initiated, however, can vary among tufrom the lower grade astrocytomas histologically (Louis et al., mors, depending on the type of malignancy and the microenvi-2001). Hypoxic response is triggered to a large extent by the hypronment in which the tumor develops.
Astrocytomas, a class of malignant brain tumors, are very oxia inducible factor-1, or HIF-1, which is composed of a basic helix-loop-helix transcription factor dimer. This dimer has two oxygen dependent (Brat et al., 2003) . Interestingly, low-grade astrocytomas first acquire their blood supply by coopting existcomponents: HIF-1␤, also known as ARNT, which is constitutively expressed, and HIF-1␣, which is regulated posttransing normal brain blood vessels, without initiating angiogenesis. However, when grade III astrocytomas progress to grade IV lationally by ubiquitination-triggered proteolysis (Semenza, 2002b) . HIF-1 controls the expression of more than 40 target astrocytomas/glioblastomas (the most malignant form of astrocytoma, also known as glioblastoma multiformae, or GBM), they genes, whose protein products are implicated in angiogenesis, metabolism, and cell survival (Semenza, 2002a) . Although three show features of hypoxic and necrotic palisades. These palisades are in part caused by vessel regression (Holash et al., HIF-␣ proteins have been discovered, targeted deletion of the HIF-1␣ gene results in loss of hypoxic responsiveness of virtually extant tissue microenvironment and involves VEGF-dependent and -independent mechanisms. every HIF-1-regulated transcript (Ryan et al., 2000) .
Interestingly, HIF-1␣ is overexpressed in human glioblasResults toma biopsies, and the level of expression is correlated with highest grade of malignancy in human GBM (Zagzag et al. ,
Generation of HIF-1␣-deficient (HIFko) astrocytomas 2000). Among the most prominent target genes of HIF-1␣ is
We isolated astrocytes from the hippocampus of mice homozythe angiogenic factor VEGF, which is also highly expressed in gous for a HIF-1␣/loxP allele ( Figure 1A ). To assure aggressive glioblastomas (Chaudhry et al., 2001) . These data suggest that tumor formation, we immortalized and transformed them with HIF-1␣ and VEGF may be tumor-promoting factors in astrocy-SV40 large T antigen and the V12-H-ras oncogene, respectively toma progression.
( Figure 1A ). V12H-ras was chosen because activation of the Several laboratories have demonstrated that loss of the HIFp21-ras pathway has been implicated in astrocytoma prolifera-1␣ transcription factor results in reduced growth rates of various tion and angiogenesis (Feldkamp et al., 1999; Guha et al., 1997) , tumors, accompanied in some, but not all, models by decreased and mouse strains expressing V12-H-ras under the control of a vascular density (Maxwell et al., 1997; Ryan et al., 1998 Ryan et al., , 2000 .
glial cell-specific promoter (GFAP) have been shown to develop Other studies, however, have pointed in the opposite direction, high-grade astrocytomas (Ding et al., 2001) . Similarly, SV40 describing HIF-1␣ as a tumor suppressor, whose loss gives large T antigen binds, and thereby inactivates, the two tumor rise to more aggressively growing embryonic stem cell-derived suppressor proteins p53 and Rb that are commonly lost in teratocarcinomas (Carmeliet et al., 1998) . Thus, the role of the astrocytoma progression (Louis et al., 2001; Xiao et al., 2002) ; hypoxic response, and HIF-1␣ specifically, during tumor growth in addition, transgenic mice expressing the Rb binding form of has been controversial. SV40 large T antigen in astrocytes also develop high-grade One of the confounding variables in these studies has been astrocytomas (Xiao et al., 2002) . the use of a range of cell types (e.g., hepatomas and fibrosarTo obtain HIF-1␣-null (also known as HIFko) astrocytomas, comas) and different cell lines within those cell types (e.g., differwe infected transformed HIF-1␣ loxP astrocytes with an adenoent embryonic stem [ES] cell lines). This makes comparative virus that expresses the bacteriophage recombinase Cre, or with studies of the divergent tumors even more difficult to interpret, a control virus expressing ␤-galactosidase. The recombinase with respect to determining the actual role of hypoxic response efficiently deleted the floxed gene sequences present on the during tumorigenesis in vivo.
two conditional HIF-1␣ alleles, creating HIF-1␣-deficient (HIFko) One of the variables not extensively analyzed thus far in the astrocytomas; real time-PCR analysis did not detect any nonreexperimental study of HIF-1␣-deficient tumors is the relationcombinant wild-type cells in adenoviral cre-infected cultures ship of site of malignancy to tumor progression. Most studies of (data not shown). The adenovirus-treated control astrocytomas tumor formation have been performed in immunocompromised did not elicit any recombination and were defined as HIF-1␣ mouse models at subcutaneous sites. Although this is a historic wild-type (also known as HIFwt) astrocytomas ( Figure 1A ). This and well-studied site of tumor growth, the subcutaneous space multistep procedure allows a dissection of the role of HIF-1␣ has a number of intrinsic peculiarities that set it apart from sites in astrocytomas without the complications of using genetically altered and possibly diverged cell lines, because transformation elsewhere in the mammalian body. These include a lack of is carried out prior to the removal of the HIF-1␣ gene by Cre spatial constraints in the form of matrix or skeletal elements, recombinase activity; deletion then occurs at a very low passage relatively sparse vascularization, and the interface of a number number. of different tissue types (fat, muscle, connective tissue) found HIFko astrocytoma cells did not induce transcription of the immediately under the skin.
HIF-1␣-regulated genes phosphoglycerate kinase (PGK) and The role of the tissue vasculature is particularly important glucose transporter-1 (Glut-1) under hypoxic conditions, whereas when considering the hypoxic response of tumors. Tumors vary HIFwt cells revealed 2-to 6-fold higher RNA levels of those tremendously from tissue to tissue in degrees of invasiveness, genes when oxygen levels were decreased ( Figure 1B ). Slightly levels of vascular density, and metastatic potential. How much increased VEGF levels were still observed in HIFko cells because of this variation is related to the state of the vasculature in the VEGF mRNA expression and stabilization is regulated by differtissue itself? This is a particularly critical issue when studying ent mechanisms. Loss of hypoxic response through HIF-1␣ the role of the HIF-1 transcription factor, which is activated by did not substantially affect cell growth of astrocytomas in vitro alterations in the microenvironment that are controlled by the ( Figure 1C ), nor did it change the transformation status of those local vasculature. It is important to note that many GBM studies cells as evaluated in a soft agar assay ( Figure 1D ). still involve mouse models in which tumors grow subcutaneously, in a poorly vascularized environment (Huang et al., 1995;  Subcutaneous growth of HIF-1␣-deficient Ozawa et al., 1998; Prewett et al., 1999) ; this contrasts strongly astrocytomas is impaired with their natural habitat, the highly vascularized brain parenWe next assessed the role of HIF-1␣ transcriptional response chyma.
in astrocytomas in a standard assay for tumorigenic potential We investigated whether HIF-1␣ activity and its downstream in vivo, in which HIFwt and HIFko astrocytoma cell lines were target, the angiogenic factor VEGF, are driving forces in astrocyinjected subcutaneously into nude mice. Not only did HIFko toma progression by generating HIF-1␣-and VEGF-deficient astrocytomas grow more slowly than wild-type astrocytomas, astrocytomas, and analyzed tumor propagation in two different reaching only 40% of the wild-type tumor weight at 21 days microenvironments, the subcutaneous and intracranial habitat. postinjection ( Figure 2A ), but there were also 30% fewer proliferOur study demonstrates that the HIF-1␣-regulated hypoxic reating cells relative to wild-type astrocytomas ( Figure 2B ). Surprisingly, we did not observe any differences in the number of sponse to the microenvironment is highly dependent on the A: Primary hippocampal astrocytes were isolated from HIF-1␣ loxP mice, immortalized, and transformed with SV40Tag and H-ras. HIF-1␣-deficient transformed astrocytes were obtained with the bacteriophage recombinase Cre by deleting the floxed gene sequences of the HIF-1␣ alleles. B: HIFwt and HIFko astrocytoma cells were cultured for 8 hr under hypoxic (0.5% pO 2 ) and normoxic (20% pO 2 ) conditions, harvested, and transcription levels of the hypoxia target genes Pgk, Glut-1, and Vegf A (all isoforms) determined by real-time PCR analysis. Induction of gene transcription was observed in HIFwt but not in HIFko astrocytes, under hypoxic conditions. Normoxia revealed similar expression levels of these genes in both cell lines. Error bars indicate SEM. C: Growth rate of HIFwt and HIFko transformed astrocytes under normoxic (20% pO 2 ) and hypoxic (0.5% pO 2 ) conditions. The growth rates of HIF wt and HIFko cells did not differ under low and high oxygen conditions. D: HIFwt and HIFko transformed astrocytes formed similar numbers and sizes of colonies in a soft agar colony formation assay. Error bars indicate standard deviation (SD).
apoptotic cells ( Figure 2C ). However, more than 70% of the HIF-1␣-deficient astrocytomas show increased cell proliferation in the brain but not in the small HIFko tumor nodules had hypoxic and necrotic areas, in contrast to wild-type control astrocytomas, which exhibited subcutaneous habitat We then injected HIFwt and HIFko astrocytomas intracranially much smaller areas of hypoxic and necrotic palisades (Figures 2E and 2F) . The morphology of the tumor cells in the two genointo the brain parenchyma of nude mice, and compared the tumor phenotypes observed to the features of astrocytomas types was indistinguishable ( Figures 3A and 3B) , and both wildtype and HIFko astrocytomas grew as encapsulated nodules grown subcutaneously. Both HIFwt and HIFko astrocytomas showed typical features of high-grade gliomas: in particular, (Figures 3C and 3D ).
infiltrative behavior of the intracerebrally placed tumors in fact nicely mimics the phenotypes observed in human astrocytomas. The tumor cells grew along existing blood vessels in the perivascular (Virchow-Robin) spaces in the brain ( Figures 6C and 6D ) and tracked along leptomeninges. To our surprise, however, HIFko astrocytomas invaded even into the collateral hemisphere, being detectable at different locations in both hemispheres of the brain ( Figure 6B ), as visualized by SV40 large T antigen staining (which specifically detects the injected tumor cells).
Although HIFwt astrocytomas were also diffusely growing ( Figure 6C ), they stayed focally localized-even at large sizes as illustrated in Figure 6A -whereas HIFko tumors did not. We were able to observe small clusters or even single HIF-1␣- plantation. HIFko tumors had become more proliferative, and invasive, without showing features of large necrotic centers once implanted intracranially. they were fast growing, and elicited hypoxic and necrotic pali-
The microenvironment radically alters vascular structure sades. However, striking differences were observed. Mice bearand density in experimental astrocytomas, ing HIFwt or HIFko astrocytomas had similar survival times, of in a HIF-1␣-dependent fashion approximately 16-18 days ( Figure 4C ). This finding indicated Based on the results above, we suspected that loss of HIF-1␣ that HIF-1␣-deficient astrocytomas were not smaller than wildmight affect tumor vascularization differentially in these two type control tumors in the intracranial habitat which was contumor sites. We sought therefore to visualize and analyze the firmed by MRI (data not shown) and histopathological analyses vascular phenotype of both subcutaneous and intracranial ( Figures 5A and 5B). astrocytoma-derived tumors by perfusing the circulatory system In contrast to subcutaneously grown astrocytomas, where with a fluorescent lectin ( Figure 7 ). We found that subcutaneous the number of dividing cells declined by 30% in the absence HIFko astrocytomas were rather poorly vascularized, with small of HIF-1␣ ( Figure 2B ), the number of proliferating cells in intrapatches of distorted blood vessels that surrounded hypoxic cranial HIFko astrocytomas was 30% higher than that in wildand necrotic areas ( Figure 7D ), and vessel densities of only type tumors ( Figure 4A ). No differences in the apoptotic index 52 vessels/mm 2 ( Figure 7E ). Wild-type astrocytomas contained were observed between wild-type and HIFko astrocytomas (Fig- 50% more blood vessels per unit area than subcutaneous HIFko ure 4B).
tumors (105 vessels/mm 2 ; Figure 7E ), a differential likely responInterestingly, HIFwt astrocytomas could often be distinsible in part for the relatively robust growth of the wild-type guished morphologically from HIFko astrocytomas. Astrocytotumor cells at this site (Figures 7C and 7E) . mas deficient in HIF-1␣ appeared more spindle-like than wildSurprisingly, HIFko astrocytomas in the brain were not only type astrocytomas, which also contained mixed cell types (e.g., highly vascularized ( Figure 7B ), but they also exhibited about giant cells (Figures 5A and 5B) . Most surprisingly, HIFko astrocy-50% more blood vessels than the wild-type control astrocytotomas did not reveal large necrotic and hemorrhagic centers mas ( Figure 7E ); this is the exact opposite of the finding in ( Figures 5A-5D ) but contained only small areas of hypoxic palisubcutaneous growth. The vessel density of HIFko tumors, howsades, in contrast to the much larger areas seen in wild-type ever, was still lower than the vessel density of normal brain, a control astrocytomas (Figures 5C and 5D) . It is important to highly vascularized organ (380 vessels/mm 2 in normal brain vernote, however, that HIF-1␣-deficient and wild-type astrocytosus 269 vessels/mm 2 in HIFko astrocytomas) ( Figure 7E ). It is mas were both defined as grade IV or mixed grade III/IV astrocyimportant to note in this context that most tumors, including tomas by our pathologist.
astrocytomas, exhibit a lower vessel density than the corresponding normal tissue because their oxygen consumption is Loss of HIF-1␣ increases the invasive capacity lower than that of normal tissue (Eberhard et al., 2000 ; Hlatky of astrocytomas in the brain but not in the et al., 2002) . The majority of HIFko astrocytoma vessels resemsubcutaneous habitat bled the morphology of the vascular network in normal brain One important feature of both genotypes of astrocytomas was ( Figure 7B and 7F), appearing slim and organized. This is in their diffuse growth into the brain parenchyma contrast to blood vessels of HIFwt astrocytomas, which exhibthat contrasted with the encapsulated phenotype of the same tumor lines grown subcutaneously ( Figures 3C and 3D ). The ited typical features of a tumor vasculature; i.e., the vessels were irregularly shaped, distorted, dilated, and leaky, as indicated by brain vasculature. This would explain the increased degree of invasion of these fast-growing tumors, likely dictated by the extravasation of fluorescent lectin into the brain parenchyma ( Figure 7A ). The most striking differences in vascular morpholnecessity to retrieve sufficient oxygen and nutrients. If this hyogy and density were apparent between HIFko astrocytomas pothesis holds true, then one would expect differing levels of in the subcutaneous area and brain. Subcutaneous tumors reangiogenic factors in HIFwt and HIFko astrocytomas. What is duced to less than 20% in vessel density compared to intracranthe downstream factor of the HIF pathway that determines ial HIFko tumors, only exposing small patches of distorted blood whether vessels will be coopted or neovascularization will be vessels ( Figures 7E, 7B , and 7D) in contrast to the dense and initiated? elongated vasculature of HIFko tumors in the brain parenchyma. HIFwt astrocytomas had similar vessel densities in both setLoss of VEGF limits tumor growth and regresses coopted blood vessels in the brain tings, but with differences in vessel branching and morphology of the vasculature between the necrotic areas that covered the VEGF-A (also known as VEGF) is highly expressed in grade IV astrocytomas/glioblastomas (GBM) and the most prominent tumor ( Figures 7A and 7C ). The vasculature of subcutaneous HIFwt astrocytomas appeared less distorted, and showed signs angiogenic candidate, because its transcription is partly induced by the HIF-1 complex (Ferrara et al., 2003 ; Pugh and Ratcliffe, of decreased branching, in comparison to the intracranial HIFwt astrocytomas ( Figures 7A and 7C) . The surprising result, that 2003) . We analyzed VEGF RNA and protein levels in HIFwt and HIFko cell lines and tumors. VEGF RNA and protein was the vasculature of intracranial HIFko tumors resembles normal brain blood vessels, suggests that these tumors have not underexpressed in both cell lines under normoxic conditions, and was induced under hypoxic conditions, albeit to a lesser degree gone neovascularization yet, but coopted the existing normal in HIFko cells (Figures 1B and 7G) . VEGF positive cells were also detected in intracranially and subcutaneously growing HIFwt and HIFko astrocytomas as revealed by immunohistoserved in HIFwt and HIFko astrocytomas are dependent on chemical analysis (Supplemental Figures S1 and S2 ). Although downstream activity of VEGF, we generated transformed the VEGF expression pattern was very heterogeneous at differastrocyte cell lines that were deficient in VEGF. Would tumors ent areas within the tumors, intracranial HIFko tumors appeared deficient in VEGF behave like those that are deficient in HIFto have overall lower levels of VEGF protein than the wild-type 1␣? We employed an approach similar to that described for controls, whereas subcutaneous HIFwt and HIFko tumors both the generation of HIFko astrocytomas ( Figure 1A ) by isolating exhibited VEGF levels predominantly around perinecrotic paliastrocytes from VEGFloxP mice, wherein exon 3 of the VEGF sades (Supplemental Figure S2) .
In order to determine whether the differing phenotypes obgene is flanked by loxP recombination sites (Gerber et al., 1999). We then immortalized and transformed VEGFloxP astrocytes ( Figures 8B and 8C ). VEGFko tumors in the subcutaneous habitat and brain elicited a significantly lower proliferation rate (Figwith SV40Tag and V12H-ras oncogenes, and in situ excised the floxed exon 3 of the VEGF gene with an adenovirus expressing ure 8C), and exhibited a higher apoptotic rate than wild-type tumors ( Figure 8D ). recombinase Cre (VEGFko astrocytomas). Infection with a control adenovirus expressing ␤-galactosidase was carried out as Histopathological analysis revealed more necrotic and hypoxic areas in subcutaneously growing VEGFko tumors comcontrol, resulting in VEGF wild-type astrocytomas (also known as VEGFwt).
pared to VEGFwt tumors (B.B., unpublished data) that can be partly explained by the 50% lower vascular density in VEGFBoth cell lines were then implanted subcutaneously and intracranially, tumor growth was observed, and dissected tudeficient subcutaneous astrocytomas ( Figure 8E ). These results are similar to those obtained from subcutaneous HIFko and mors were analyzed for their morphology, proliferation and apoptotic rates, and vascular profile. Similar to HIF-1␣-deficient HIFwt tumors ( Figures 3A-3C and 7E ). There were, however, significant differences between VEGFko and HIFko tumors in tumors, VEGFko astrocytomas grew much slower subcutaneously than the control VEGFwt tumors, reaching only about 50% the brain parenchyma. VEGFko tumors (Figure 8Fb ) did not form real tumor masses like VEGFwt (Figure 8Fa ) or HIFko tumors of the wild-type tumor weight at 21 days postinjection ( Figure  8A ). We observed, however, striking differences between HIFko ( Figure 5B ). Those tumors that were still defined as gradeIII/IV astrocytomas grew rather in migrating clusters, with necrosis and VEGFko tumors in the brain. VEGFko astrocytomas grew slower than the control astrocytomas in the brain parenchyma, in some of the centers that were encircled by vascular tumor nests (Figure 8Fb ). Despite this diffusely growing phenotype, and mice had a statistically significant prolonged mean survival of 30%, compared to mice bearing VEGFwt tumors (p Ͻ 0.001) VEGF-deficient tumors were not detected in both brain hemi- E) show a 50% reduction in vessel density compared to s.c. HIFwt tumors (p ϭ 0.0317) (C and E), exposing small patches of distorted and leaky vessels. In contrast, intracranial HIFko tumors are highly vascularized (5-fold higher than s.c. HIFko tumors) and reveal a 50% induction of vessel density in comparison to intracranial HIFwt astrocytomas (p ϭ 0.0159) (E). Intracranial HIFko tumor vessels resemble normal brain blood vessels but show reduced vessel density in comparison to normal brain (B and F) in contrast to the distorted, dilated, and leaky vessels of intracranial HIFwt tumors in (A). F: Vasculature of normal brain. G: VEGF protein levels were assessed in conditioned medium of HIFwt and HIFko cells under normoxic and hypoxic (24 hr) conditions by an ELISA assay. VEGF protein levels are elevated in both cell lines under low oxygen levels.
spheres, but stayed focally localized, in striking contrast to the network of more normal, elongated brain vessels ( Figure 7B ), VEGF-deficient tumors revealed a low density of distorted blood widespread dissemination of HIFko tumors. The distinct invasive patterns may be attributed to the differing vascular phenotype vessels; the vasculature was reduced by about 45% relative to VEGFwt tumors ( Figures 8E, 8Fc, and 8Fd) . The same relative of both tumor types. Whereas HIFko tumors contained a dense note that it is a hallmark of most tumors that they exhibit a lower oxygen consumption rate, and therefore a lower vessel density, than the corresponding normal tissue, allowing tumor cells to accumulate between capillaries and thereby expanding the invascular phenotype was observed in subcutaneously growing tercapillary distance (Eberhard et al., 2000; Hlatky et al., 2002) .
The hypoxic response is dependent

VEGFwt and VEGFko tumors; the vasculature of VEGFko tumors
This also holds true for high-grade astrocytomas, because their was also reduced by about 50% (Figures 8E, 8Fe , and 8Ff).
microvessel density is lower than that of normal brain tissue In summary, loss of VEGF in astrocytomas reduced subcuta- (Eberhard et al., 2000) . neous and intracerebral tumor growth by severely impairing Interestingly, low-grade astrocytomas first coopt existing growth and survival of coopted tumor vessels. The tumors rebrain vessels, and propagate along them; only when these tuacted differently to the regressing vessels: subcutaneous tumors progress into grade IV astrocytomas/GBM do they bemors became very necrotic, and showed increased apoptosis, come neovascularized. It is a peculiar feature of glioblastomas whereas intracerebral tumors grew along blood vessels in mithat they first regress the normal coopted blood vessels within grating clusters, albeit only in close conjunction to the tumor the tumor mass before they form new tumor vessels; these (Table 1) . Collectively, these results indicate that the hypoxic are morphologically very distinct from the normal vasculature response of a tumor can determine initiation of new blood ves- (Holash et al., 1999a (Holash et al., , 1999b . sels, or cooption of existing blood vessels, but is highly depenBlood vessel regression in astrocytomas is partly caused dent on the local environment in which those tumors arise.
by Angiopoietin-2 (Ang2), a ligand of the receptor tyrosine kinase Tie-2, which is expressed in endothelial cells (Maisonpierre et Discussion al., 1997; Yancopoulos et al., 2000) . Ang2 is induced early, when We have made the unexpected observation that HIF-1␣ can act oxygen levels drop (Abdulmalek et al., 2001) , and causes blood as a negative or positive factor in astrocytoma progression, vessel regression in the absence of VEGF, but as soon as VEGF dependent on the microenvironment in which tumors grow. Loss is induced, it will synergize with VEGF in new blood vessel of HIF-1␣ impairs astrocytoma growth subcutaneously, but information (Hanahan, 1997) . We have obtained preliminary data creases proliferative and invasive properties of astrocytomas indicating that Ang2 levels are elevated in intracranial HIFwt, but in the brain. These effects are not observed when VEGF, a not in HIFko astrocytomas (G.B. and Jocelyn Holash, Regeneron downstream target of HIF-1␣, is genetically ablated in astrocytoInc., unpublished data). The high levels of Ang2 and the relatively mas (Table 1) . VEGF-deficient astrocytomas exhibit a growth low vessel density further support the notion that the vasculature disadvantage in either microenvironment.
of HIFwt tumors undergoes regression and remodeling as indiHow can these opposite effects be explained? Hypoxia is cated by the appearance of more tortuous and distorted tumor a hallmark of grade IV astrocytomas/glioblastomas (GBM), and blood vessels (Holash et al., 1999a (Holash et al., , 1999b Zagzag et al., 2000) . enables these tumors to partly induce angiogenesis in a HIFIn contrast, HIFko tumors express much lower levels of Ang 2 1␣-dependent manner. HIF-1␣ and its target VEGF are both and consist of more densely packed elongated blood vessels, highly upregulated in GBMs, and vascular proliferation is a progsimilar to vessels of normal brain, suggesting that these vessels nostic marker in GBMs that distinguishes them from lower grade have not undergone a transition to an angiogenic tumor vasculaastrocytomas. In agreement with predicted behaviors of the ture. tumors, our subcutaneous astrocytoma studies reveal that loss Taken together, these observations suggest that HIF-1␣-of HIF-1␣, or VEGF, results in poorly vascularized tumors, and deficient astrocytomas are unable to induce angiogenesis, but causes severe necrosis and restrained growth in the subcutanethat they adapt to this disadvantage by behaving like lowerous space. Thus, loss of HIF-1␣ or VEGF activity severely imgrade astrocytomas; i.e., they take advantage of the highly vaspaired astrocytoma growth. These data are in consensus with cularized environment, and migrate along existing normal blood results of other laboratories: that absence of HIF-1␣ in ES cellvessels to propagate. Notably, HIFwt as well as HIFko astrocytoderived tumors resulted in reduced vascularization within the mas were histopathologically both defined as grade III/IV or tumor due to a reduced capacity to induce VEGF expression grade IV astrocytomas. by hypoxia (Carmeliet et al., 1998; Ryan et al., 1998; Tsuzuki Based on these results, one would expect that VEGFko et al., 2000) . Similarly, genetic ablation of VEGF has been shown astrocytomas behave similarly to HIFko tumors, and exhibit to cause a dramatic reduction in vascularity and growth of variincreased invasive behavior in tumor cells, specifically around ous tumors (Grunstein et al., 1999; Inoue et al., 2002; Tsuzuki et al., 2000) .
normal blood vessels in the brain parenchyma. Surprisingly, VEGF-gene ablation in astrocytomas did not induce the phenonumber of studies, although these have been exclusively embryonic stem cell-derived teratocarcinomas, injected subcutanetypes observed in HIFko astrocytomas when grown intracranially (summarized in Table 1 ). Whereas HIFko tumors grew faster ously (Carmeliet et al., 1998) . Our study illustrates that the HIF-1␣-mediated pathway can positively or negatively influence the than the wild-type tumors, VEGFko astrocytomas were at a growth disadvantage. This may be again attributed to their vasfate and behavior of a tumor, such as an astrocytoma, but this influence is dependent upon the microenvironment. This cular phenotypes: in the brain, HIFko tumors were well vascularized, but VEGFko tumors were poorly vascularized. How can is nicely demonstrated in the cell cycle regulation of HIFko astrocytomas. Loss of HIF-1␣ in astrocytomas in the brain rethese discrepancies be explained? Loss of HIF-1␣ disables hypoxia-dependent VEGF induction, but we found that HIF-1␣-defivealed a higher proliferation index which is similar to the finding by Goda et al. that p53-deficient fibroblasts and B lymphocytes cient tumors still express VEGF, likely due to a combination of hypoxia-induced stabilization of VEGF mRNA, transcriptional incan be further pushed into cell cycle when HIF-1␣ is absent (Goda et al., 2003) . The same transformed HIFko astrocytes, duction by oncogenes such as H-ras, and VEGF expression of host cells within the tumor. The somewhat lower VEGF levels however, behave the opposite when transplanted into the subcutaneous space; i.e., they grow slower than the control astrocymaybe sufficient to keep coopted brain vessels functional, but are not adequate to initiate angiogenesis. Moreover, other additomas, supporting the notion that the microenvironment is an additional crucial player in cell cycle regulation. Indeed, intrational mechanisms, such as downregulation of angiogenic inhibitors like thrombospondin-1, might be necessary to induce the cranial HIFko astrocytomas are not very hypoxic and necrotic and well vascularized, which is an environment that would favor angiogenic switch (Watnick et al., 2003) . The situation changes when VEGF is ablated in tumor cells: although tumors form tumor cell growth. In contrast, HIF-1␣-deficient astrocytomas in the subcutaneous space are extremely hypoxic and necrotic nests around coopting blood vessels, those start to regress, which in turn keeps tumor cell proliferation limited. One may and poorly vascularized, a harsh environment that limits tumor cell growth. argue that the VEGF levels in intracranial VEGFko tumors, made by host cells, are not sufficient to support the existing vasculature of the growing tumor. The differing phenotypes of HIFko Implications for cancer therapy Our observation of intracranial HIFko astrocytomas also has and VEGFko astrocytomas indicate that other factors than VEGF are likely to be involved in the adaptation of HIF-1␣-deficient implications for therapy based on HIF-1␣ targeted inhibition. tumors to propagate without initiating angiogenesis. ImporOur data suggest that inhibition of HIF-1␣, thereby impairing tantly, the adaptation to become more invasive is also depenthe hypoxic response, might not be a desired strategy to treat dent on the microenvironment, suggesting an interaction beastrocytomas, as they might adapt by becoming more invasive tween tumor cells and host factors in the extracellular matrix and infiltrative. of the brain parenchyma.
Interestingly, gene ablation of VEGF in astrocytomas exhibWhy do HIFko astrocytomas not coopt blood vessels in the ited a growth disadvantage both in the subcutaneous space subdermis, and become more invasive as they do in the brain? and the brain, eliciting decreased proliferation rate and vessel The subcutaneous environment is a very vessel-poor space that density when compared to wild-type astrocytomas, arguing that requires extensive recruitment and cooptation of vessels for regressing and impairing tumor vessels is a limiting step and tumor survival. In this context, loss of HIF-1␣ or VEGF, and a desired therapeutic approach for astrocytomas. This is in subsequent loss of angiogenic capacity, is likely a negative agreement with the findings that functional ablation of VEGF factor, resulting in fewer vessels, less proliferation, and slower activity with a neutralizing antibody directed against VEGF regrowth. This demonstrates that vessel recruitment and angiosulted in vessel reduction, decreased tumor growth, and ingenesis are parameters that affect tumor growth in highly varicreased apoptosis in a rat model of glioblastomas (Rubenstein able ways. It is quite possible that the differing effects seen due et al., 2000) . to loss of HIF-1␣ in other laboratories are also tightly linked, In summary, these results emphasize that the microenvironnot to the cell line involved, but to variations in the space in ment has to be taken into consideration to better understand which transplanted tumors grow.
tumor behavior and adaptation in response to treatment modalOne could certainly argue that tumors deficient in HIF-1␣ ities. Indeed, our findings are confirmed by several reports demmay adapt other conduits to survive than the ones that we onstrating that the microenvironment and tumor location funcsuggested above. Alternative paths by H-ras or p53-deficiency tionally impacts tumor growth and metastasis. Many tumors due to ectopic expression of SV40Tag can be likely excluded, have different behaviors when inoculated at sites different from because astrocytes were first transformed with these oncotheir natural environment, most commonly in subcutaneous genes before HIF-1␣ was deleted, leading to genetically identisites; they become encapsulated, lose their metastatic behavior, cal cell lines, except for HIF-1␣ ablation. It is also unlikely that change their morphology, and, indeed, respond differently to HIF-2␣ compensates for HIF-1␣ deficiency in the transformed treatment (Cuenca et al., 1996; MacDonald et al., 2001 ; Miyoshi astrocyte cells because we have analyzed HIF-2␣ protein levels et al., 2000; Taillandier et al., 2003) . in HIFwt and HIFko astrocytoma cell lines, and our preliminary Experimental procedures data suggest that HIF-2␣ protein is present in our transformed astrocyte lines, but at low levels, and does not appear to be , 2003) . The role of HIF-1␣ as a potential lox P sites of the second exon of the Hif1-␣ allele (Ryan et al., 2000) , whereas VEGFϩ f /ϩ f mice contain flanked lox P sites within exon 3 of the VEGF gene "negative factor" in tumorigenesis has been implied by a smaller (Gerber et al., 1999) . Astrocytes of both mouse strains were isolated as Subcutaneous implantation of HIFwt and HIF Ϫ/Ϫ , and VEGFwt and VEGF Ϫ/Ϫ transformed astrocytes follows: briefly, after removal of the meninges, the hippocampus was di-22 athymic mice (4-6 weeks of age; Simonsen laboratory, San Jose, CA) gested with papain (Worthington Biochemical Corporation, Lakewood, NJ) were implanted subcutaneously with either 100 l of 1 ϫ 10 7 HIFwt, or 8 at a final concentration of 45 units/ml in a standard enzyme solution conathymic mice with 1 ϫ 10 7 VEGFwt transformed astrocytes. 21 athymic mice taining 50 mM EDTA, 150 mM CaCl 2 , 100 mM L-cysteine, and 0.1 g/ml were injected subcutaneously with 100 l of 1 ϫ 10 7 HIFko or 8 mice with Dnase in a solution consisting of 1 M HANKS, 10 mM HEPES (Invitrogen, 1 ϫ 10 7 VEGFko transformed astrocytes. 21 days postimplantation, tumors Carlsbad, CA), and 7.5% NaHCO 3 . The enzyme solution was aspirated and were harvested, weighed, and processed as described below for immunohisthe digested tissue was washed in astrocyte tissue culture medium: BME tochemical analyses. All implantation experiments were repeated up to two supplemented with 10% FBS, 1% penicillin/streptromycin, 1% sodium pyrutimes. vate (all from Invitrogen), 0.6% glucose (Fisher, Los Angeles, CA), and 0.1% mito-serum extender (Becton Dickinson Biosciences, La Jolla, CA). SingleIntracranial implantation of HIFwt and HIF Ϫ/Ϫ , and VEGFwt cell suspensions were cultured in the medium described and grown at 37ЊC
and VEGF Ϫ/Ϫ transformed astrocytes in a humidified incubator containing 5% CO 2 . After one week, primary 35 athymic mice (4-6 weeks of age; Simonsen laboratory, San Jose, CA) astrocytes were purified by shaking the flasks on a rotator at RT at 300 rpm were implanted intracranially with either 2.5 l of 0.7 ϫ 10 6 HIFwt or with (Innova 2000, New Brunswick Scientific, Edison, NJ) and purity confirmed 2.5 l of 0.7 ϫ 10 6 HIFko-transformed astrocytes. Similarly, six mice were with an anti-GFAP antibody. Next, cells were immortalized by stable transfecinjected with VEGFwt astrocytomas and eight mice with VEGFko-transtion with a SV-40 Large T antigen DNA construct. This was carried out by formed astrocytes. Transplantation site was exactly 2 mm deep into the electroporation of pMC1neo Poly A (Stratagene, La Jolla, CA) and SV-40 brain parenchyma and 3 mm to the right of the midline behind the breegma Large T antigen using a BioRad Gene Pulser 2, set at 975 F, ∞ resistance using a Hamilton syringe. All the mice were sacrificed between 15 to 21 and 250 volts. Starting 48 hr posttransfection, stably transfected cells underdays postimplantation when they showed side effects of tumor expansion went G418 selection (300 g/ml; Invitrogen). Resistant colonies were pooled such as lateral recumbency and weight loss. Mice were anesthetized, heartand transformed by transfection of a retrovirus containing the H-Ras oncoperfused with 4% paraformaldehyde (PFA), and then brains either embedded gene. Thereby, cells were plated in 6-well plates (Corning) at a density of into paraffin or frozen into OCT medium. All implantation experiments were 7 ϫ 10 4 cells/well in BME and virus was added to the cells in combination with repeated up to three times. polybrene (Sigma, St. Louis, MO) at 4 g/ml and medium. 48 hr postinfection, stably transfected cells were selected by Puromycin (Sigma) at a concentraVisualization of the vasculature tion of 1 g/ml. After about 7 to 9 days, clones appeared, and they were
To visualize blood vessels in tumors and normal tissue, mice were first pooled to obtain a heterogenous group of stably transformed cells, which anesthetized and injected (i.v.) with 0.05 mg FITC-labeled tomato lectin were grown in the same medium, containing 5% FBS (Invitrogen). Next, (lycopersicon esculentum; Vector Laboratories, Burlingame, CA) and then the Hif1-␣ exon 2 was deleted by transfecting the cells transiently with an heart-perfused with 4% paraformaldehyde (PFA). Brains were frozen in OCT, adenovirus expressing either cre recombinase or ␤-galactoside (MOCK). To sectioned at 50 m, and appropriate sections mounted. determine the efficiency of Hif1-␣ deletion, genomic DNA was isolated from the cells and the recombination frequency was analyzed by TaqMan Real Detection of hypoxic areas in tumors Time PCR analysis.
To allow assessment of the hypoxic regions within tumors, mice were injected i.p. with 60 mg/kg (in w/v PBS) pimonidazole (Hydroxyprobe-1TM, Growth curve and soft agar assay Natural Pharmacia International Inc.), 1.5 hr prior to sacrifice. Tumors were For the growth curve, cells were plated in 12-well plates (Corning) in tripliresected, processed, and embedded into paraffin. 5 m sections were cates at a density of 1 ϫ 10 5 cells/well in the described tissue culture medium treated with 0.01% pronase for 40 min. at RT, washed, and incubated with for transformed astrocytes. Cells were exposed to normoxia 20% pO 2 and Hydroxyprobe-1 mouse monoclonal antibody 1(MAb1; Natural Pharmacia hypoxia 0.5% pO 2 for up to 96 hr. Cell counts were performed in duplicate
International Inc) at a 1:50 dilution for 40 min at RT. A secondary biotinylated at each time point using a hemacytometer. For the soft agar assay, cells goat-anti mouse IgG antibody was applied, and staining visualized using were plated in triplicates in a 6-well plate at 5 ϫ 10 5 cells/well, mixed in the DAB chromophore (Vector ABC; DAB). Sections were rinsed and counter-0.35% LMP agarose (Invitrogen, Carlsbad, CA). After culturing the cells for stained with hematoxylin. 21 days, the wells were stained with 0.005% crystal violet for 4 hr and analyzed for colony number and size.
Immunohistochemical analysis HIFwt or HIFko astrocytoma cells in the brain were identified with a rabbit Real-time PCR assay anti-SV40 Tag antibody. Briefly, slides were deparaffinized and incubated Cells were grown in 10 cm plates (Falcon) at 7 ϫ 10 6 cells/plate and under with the anti-Tag antibody (1:500; gift from Douglas Hanahan at UCSF) normoxic and hypoxic conditions. After 8 hr incubation, total RNA was followed by treatment with a biotinylated goat anti-rabbit IgG antibody (1:200; isolated using a Qiagen RNeasy kit according to the manufacturer's instrucVector laboratories, Burlingame, CA). Antibody reactions were revealed with tions. From 1 g of total RNA, first-strand cDNA was synthesized using an ABC kit, using the chromophore 3,3-diaminobenzidine (DAB) substrate. In order to visualize tumor cells and the vasculature simultaneously, formed using 2ϫ Taq Master Mix (Perkin Elmer Applied Biosystems), 900 fluorescent immunohistochemistry was performed with the Tag antibody on nM of the forward and the reverse PCR primers, and 250 nM of a fluorescently brain cryosections of mice whose vascular system had been perfused FITCtagged primer pair-specific probe in a total volume of 25 l using default Lectin prior to euthanasia. cycling parameters on an ABI Prism 7200 Sequence Detector. The following Apoptotic index was assessed by TUNEL staining (Naik et al., 1996) , primer and probe sequences were used:
and proliferating cells were detected with a rat anti-mouse Ki-67 antibody PGK-1: (F) 5Ј-CAGGACCATTCCAAACAATCTG-3Ј; (R) 5Ј-CTGTGGTAC
(1:100; DAKO Corporation, Carpinteria, CA) followed by incubation with a TGAGAGCAGCAAGA-3Ј; (probe) 5Ј-(6FAM)TAGCTCGACCCACAGCCCTC biotinylated rabbit-anti rat IgG antibody (1:200; Vector laboratories, Burl-GGCATAT-(TAMRA)-3Ј.
ingame, CA) and DAB treatment as described above. Glut-1: (F) 5Ј-ACGAGGAGCACCGTGAAGAT-3Ј; (R) 5Ј-GGGCATGTGC TTCCAGTATGT-3Ј; (probe) 5Ј-(6FAM) CAACTGTGCGGCCCCTACGTCTTC-VEGF ELISA (BHQ)-3Ј.
HIFwt and HIFko transformed astrocyte cell lines were cultured under nor-VEGF total: (F) 5Ј-ATCCGCATGATCTGCATGG-3Ј; (R) 5Ј-AGTCCCATG moxia (20% pO 2 ) and incubated for 24 hr under hypoxic conditions (10% AAGTGATCAAGTTCA-3Ј; (probe) 5Ј-(6-FAM) TGCCCACGTCAGAGAGCAA pCO 2 ; 0.5% pO 2; ). Conditioned medium was removed and VEGF levels were assayed by a sandwich DuoSet ELISA kit (DY493, R&D Systems, San Diego, CATCAC-(BHQ)-3Ј.
Gerber, H.P., Hillan, K.J., Ryan, A.M., Kowalski, J., Keller, G.A., Rangell, L., California), according to the manufacturer's instructions. Each assay condiWright, B.D., Radtke, F., Aguet, M., and Ferrara, N. (1999) . VEGF is required tion was tested in triplicates.
for growth and survival in neonatal mice. Development 126, 1149-1159. 
Statistical analysis
